The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2023 | Advantages and applications of mass spectrometry in multiple myeloma
Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, discusses the advantages and uses of mass spectrometry (MS) in multiple myeloma. This non-invasive technique is emerging as a promising method to detect monoclonal proteins at very low levels. Dr Mai explains that in the future, MS may be used to complement the IMWG criteria and for measurable residual disease (MRD) assessment. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role, Honoraria, Research Funding, and Travel Accommodations and Expenses – Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline and Takeda.
